Daily Stock Market Report (Fri 6th February 2026) - Agenda

Good morning everyone! With the New Year reporting season well and truly finished now, I hope your portfolios have survived in good shape!

Today's Agenda is complete.
Spreadsheet accompanying this report: link.

Companies Reporting
Name (Mkt Cap)RNSSummaryOur View (Author)GSK (LON:GSK) (£88.9bn | SR94)Nucala COPD approved by the European CommissionEuropean Commission has approved Nucala (mepolizumab), a monoclonal antibody targeting interleukin-5 (IL-5), in adults as an add-on maintenance treatment for uncontrolled COPD.HgCapital Trust (LON:HGT) (£1.85bn | SR N/A)Trading Update2025 NAV total return 4%, NAV per share £5.62 (latest share price: 403.5p). HGT share price is down 20% year-to-date due to recent decline in listed software shares. “The Board is actively considering a number potential actions (sic) to address the current discount to net asset value using the full set of tools at its disposal, including share buy-backs.”Victrex (LON:VCT) (£606m | SR63)Q1 Trading UpdateQ1 volumes down 4%, revenues down 6%. “Performance in H1 2026 is expected to be weaker than H1 2025, reflecting the weaker end to Q1 and the currency headwind being weighted to the first half.” Full-year guidance unchanged.Phoenix Spree Deutschland (LON:PSDL) (£158m |...